For the Inventor, By the Inventor

Enter inventor name

Princeton, NJ, United States of America

Jerome B Zeldis

USPTO Granted Patents = 63 (Patent Applications = 25)

CIPO Patents = 7 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 1.1

ph-index = 20

Forward Citations = 1,703(Granted Patents)

Forward Citations (Not Self Cited) = 1,426(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Princetone, NJ (US) (2007 - 2008)
Princeton, NJ (US) (1999 - 2022)

Company Filing History:

Celgene Corporation

Celegene Corporation

4. 1 out of 162

Calgene Corporation

5. 1 out of 1,975

6. 1 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

7. 1 out of 169

Signal Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 1999-2022

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Multiple Myeloma

Myelodysplastic Syndromes

Immune Reconstitution Inflammatory Syndrome

Immunomodulatory Compounds

Leukemias

Non-Hodgkin's Lymphoma

Kaposi's Sarcoma

Cancer Treatment

Piperidine Derivatives

Combination Therapy

Stem Cell Transplantation

Biomarkers

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE48890 - Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation (2022-01-10),

2. 11116782 - Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine (2021-09-14),

3. 10682336 - PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) (2020-06-16),

4. 10206914 - Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation (2019-02-19),

5. 10001483 - Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (2018-06-19),

6. 9925207 - Methods of treating myelodysplastic syndromes using lenalidomide (2018-03-27),

7. 9662321 - Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents (2017-05-30),

8. 9498472 - Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias (2016-11-22),

9. 9408831 - Methods for treating respiratory viral infection (2016-08-09),

10. 9393238 - Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent (2016-07-19),

11. 9283215 - Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies (2016-03-15),

12. 9155730 - Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent (2015-10-13),

13. 9101622 - Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone (2015-08-11),

14. 9101621 - Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation (2015-08-11),

15. 9056120 - Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine (2015-06-16),

Title: Jerome B Zeldis: Pioneering Innovations in Biotechnology

Introduction:

Jerome B Zeldis, a prominent inventor, continues to shape the field of biotechnology with a relentless passion for innovation and a dedicated focus on enhancing global healthcare. With a track record of 63 patents to his name, Zeldis has become a guiding light for aspiring inventors and researchers worldwide.

Latest Patents:

Zeldis' latest patents showcase his commitment to advancing treatments for diseases like multiple myeloma and myelodysplastic syndromes. His innovative methods involve the administration of immunomodulatory compounds in combination with other active ingredients to effectively treat and manage these conditions. These patents also focus on reducing adverse side effects associated with traditional cancer therapies, offering new hope for patients.

Career Highlights:

Having worked in esteemed companies like Celgene Corporation and Therakos, Inc., Zeldis has been at the forefront of cutting-edge research and development in the biotechnology industry. His contributions have not only enhanced the quality of patient care but have also set new standards for innovation in the field.

Collaborations:

Throughout his illustrious career, Zeldis has collaborated with esteemed colleagues such as Andrew L Zeitlin and Maghsoud M Dariani. Together, they have pioneered groundbreaking research initiatives and have played a significant role in revolutionizing the treatment landscape for various medical conditions.

Conclusion:

Jerome B Zeldis' relentless pursuit of innovation and his unwavering dedication to improving global healthcare make him a true visionary in the field of biotechnology. His groundbreaking patents and collaborations serve as a testament to his impact on the industry, inspiring generations of inventors and researchers to follow in his footsteps.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…